Marijuana Rescheduling Isn’t Enough: Why the U.S. Needs Smarter Cannabis Regulation

As the federal government moves closer to rescheduling marijuana from Schedule I to Schedule III, advocates and policymakers are celebrating what appears to be a historic shift. For decades, cannabis has been classified alongside heroin, LSD, and other substances deemed to have “no accepted medical use.” A downgrade would recognize cannabis’ therapeutic potential and open doors for medical research. Yet, according to growing voices in public health and regulatory policy, rescheduling alone will not address the deeper challenges tied to legalization, especially the unregulated potency of THC products dominating today’s markets.

The Key Development

Rescheduling cannabis to Schedule III would mark a symbolic victory for reformers and provide tangible benefits. It could ease restrictions on research, reduce tax burdens on cannabis businesses by ending IRS 280E limitations, and signal federal acknowledgment of marijuana’s medicinal value. However, critics argue that this change risks being little more than a political gesture without comprehensive regulations.

The U.S. cannabis market has evolved into a $30+ billion industry, where THC potency has soared in recent years. Concentrates often exceed 80% THC, while flower averages more than double the potency of strains available in the 1990s. Advocates for stronger oversight warn that this trend, left unchecked, mirrors the trajectory of other industries where profit incentives eclipsed public health safeguards.

Impact & Implications

If cannabis is rescheduled without accompanying regulations, the industry could expand rapidly with few limits on product potency, marketing practices, or youth exposure. Public health experts worry that states may continue to experiment with widely differing rules, leaving consumers vulnerable.

For instance, Colorado and California allow high-potency concentrates, while other states impose THC caps or tighter packaging restrictions. The lack of a unified federal framework risks a patchwork market where consumer protections vary dramatically. Critics point to alcohol and tobacco as cautionary tales—industries where aggressive marketing and high-potency products created long-term health burdens.

Rescheduling may also inadvertently benefit large corporations poised to dominate the market. By reducing financial burdens such as IRS 280E, multi-state operators (MSOs) could outcompete smaller players and equity applicants, raising questions about whether social justice goals of legalization will be fulfilled.

Market & Regional Context

At the state level, cannabis regulations remain highly uneven. Some states, like New York and Connecticut, have implemented equity-focused licensing programs alongside consumer protections such as potency limits. Others, like Oklahoma, saw chaotic markets emerge with little oversight. Without federal standards, these discrepancies will persist even if marijuana’s schedule changes.

Meanwhile, Canada offers an instructive comparison. Legalized nationally in 2018, Canada regulates THC levels in edibles (10 mg per package cap) and requires strict marketing controls similar to tobacco. While the illicit market persists, Canadian regulators have prioritized public health measures over corporate expansion—something many argue the U.S. should emulate.

Looking Ahead

Rescheduling marijuana may ultimately be remembered as the first domino in broader federal reform. Yet, the next critical step will be establishing a regulatory framework that treats cannabis like neither a dangerous narcotic nor an unregulated commodity. Experts are calling for:

• THC potency caps to reduce risks of dependency and mental health issues.
• Uniform labeling and packaging standards to enhance consumer safety.
• Advertising restrictions modeled after tobacco regulations.
• Stronger protections for youth to prevent underage consumption.

The rescheduling debate also highlights a fundamental policy question: Should cannabis be regulated by the FDA like pharmaceuticals, by the TTB like alcohol, or through a hybrid model? The answer will shape the next decade of cannabis policy in America.